Dermira Company Profile (NASDAQ:DERM)

About Dermira

Dermira logoDermira, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company's portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor, that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease. DRM04 is a topical, small-molecule anticholinergic product for the treatment of hyperhidrosis. DRM01 is a topical, small-molecule sebum inhibitor for the treatment of acne.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: DERM
  • CUSIP:
Key Metrics:
  • Previous Close: $33.32
  • 50 Day Moving Average: $30.09
  • 200 Day Moving Average: $31.82
  • 52-Week Range: $17.42 - $36.34
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -13.89
  • P/E Growth: 0.00
  • Market Cap: $1.18B
  • Outstanding Shares: 35,603,000
  • Beta: 0.8
  • Return on Equity: -51.30%
  • Return on Assets: -42.90%
  • Current Ratio: 9.53%
  • Quick Ratio: 9.53%
Additional Links:
Companies Related to Dermira:

Analyst Ratings

Consensus Ratings for Dermira (NASDAQ:DERM) (?)
Ratings Breakdown: 1 Sell Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $44.75 (34.79% upside)

Analysts' Ratings History for Dermira (NASDAQ:DERM)
DateFirmActionRatingPrice TargetDetails
1/3/2017SEB Equity ResearchReiterated RatingReduceView Rating Details
10/5/2016Leerink SwannReiterated RatingBuyView Rating Details
10/3/2016Needham & Company LLCReiterated RatingPositive$46.00View Rating Details
6/2/2016WedbushBoost Price TargetOutperform$42.00 -> $46.00View Rating Details
3/16/2016Citigroup Inc.Lower Price TargetBuy$42.00 -> $40.00View Rating Details
8/19/2015Cowen and CompanyInitiated CoverageOutperform$40.00View Rating Details
8/7/2015GuggenheimBoost Price TargetBuy$22.00 -> $40.00View Rating Details
(Data available from 2/25/2015 forward)


Earnings History for Dermira (NASDAQ:DERM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016Q316($0.72)($0.72)ViewN/AView Earnings Details
5/10/2016Q1($0.94)($0.95)ViewListenView Earnings Details
3/3/2016Q4($0.95)($1.04)ViewListenView Earnings Details
11/10/2015Q3($0.77)($0.58)ViewN/AView Earnings Details
8/13/2015Q2($0.81)($0.69)ViewN/AView Earnings Details
5/12/2015Q1($0.65)($0.57)ViewN/AView Earnings Details
3/25/2015Q4($0.59)($0.29)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Dermira (NASDAQ:DERM)
Current Year EPS Consensus Estimate: $-3.41 EPS
Next Year EPS Consensus Estimate: $-2.39 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($1.00)($1.00)($1.00)
Q2 20161($0.96)($0.96)($0.96)
Q3 20161($0.64)($0.64)($0.64)
Q4 20161($0.93)($0.93)($0.93)
(Data provided by Zacks Investment Research)


Dividend History for Dermira (NASDAQ:DERM)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Dermira (NASDAQ:DERM)
Insider Ownership Percentage: 17.30%
Institutional Ownership Percentage: 84.92%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/15/2017Christopher M. GriffithSVPSell1,303$30.79$40,119.37View SEC Filing  
2/15/2017William R RingoDirectorSell500$32.00$16,000.00View SEC Filing  
2/14/2017Eugene A BauerInsiderSell1,505$30.00$45,150.00View SEC Filing  
2/1/2017Eugene A BauerInsiderSell995$30.00$29,850.00View SEC Filing  
1/17/2017Christopher M. GriffithVPSell1,303$29.11$37,930.33View SEC Filing  
1/4/2017Thomas G WiggansCEOSell8,000$31.06$248,480.00View SEC Filing  
1/4/2017William R RingoDirectorSell500$32.00$16,000.00View SEC Filing  
1/3/2017Eugene A BauerInsiderSell2,500$30.07$75,175.00View SEC Filing  
12/16/2016William R RingoDirectorSell125$32.00$4,000.00View SEC Filing  
12/15/2016Christopher M. GriffithVPSell1,303$30.70$40,002.10View SEC Filing  
12/14/2016Eugene A BauerInsiderSell2,500$30.36$75,900.00View SEC Filing  
12/1/2016Thomas G WiggansCEOSell11,000$30.80$338,800.00View SEC Filing  
12/1/2016William R RingoDirectorSell375$32.00$12,000.00View SEC Filing  
11/9/2016Andrew GuggenhimeCFOSell4,100$35.02$143,582.00View SEC Filing  
11/9/2016William R RingoDirectorSell500$32.30$16,150.00View SEC Filing  
11/1/2016Thomas G WiggansCEOSell11,000$31.19$343,090.00View SEC Filing  
10/17/2016Christopher M GriffithVPSell1,303$32.33$42,125.99View SEC Filing  
10/11/2016Andrew GuggenhimeCFOSell10,900$34.34$374,306.00View SEC Filing  
10/3/2016Thomas G WiggansCEOSell11,000$34.60$380,600.00View SEC Filing  
10/3/2016William R RingoDirectorSell500$34.25$17,125.00View SEC Filing  
9/19/2016Andrew GuggenhimeCFOSell15,000$35.01$525,150.00View SEC Filing  
9/15/2016Christopher M GriffithVPSell1,303$33.26$43,337.78View SEC Filing  
9/12/2016Andrew GuggenhimeCFOSell10,000$32.53$325,300.00View SEC Filing  
9/1/2016Thomas G WiggansCEOSell11,000$31.63$347,930.00View SEC Filing  
9/1/2016William R RingoDirectorSell500$32.00$16,000.00View SEC Filing  
8/15/2016Christopher M GriffithVPSell1,303$31.75$41,370.25View SEC Filing  
8/11/2016Andrew GuggenhimeCFOSell10,000$31.02$310,200.00View SEC Filing  
8/1/2016Eugene A BauerInsiderSell2,500$33.18$82,950.00View SEC Filing  
8/1/2016Thomas G WiggansCEOSell11,000$33.19$365,090.00View SEC Filing  
8/1/2016William R RingoDirectorSell500$33.65$16,825.00View SEC Filing  
7/15/2016Christopher M GriffithVPSell1,303$30.02$39,116.06View SEC Filing  
7/11/2016Andrew GuggenhimeCFOSell10,000$30.15$301,500.00View SEC Filing  
7/5/2016Thomas G WiggansCEOSell11,000$29.62$325,820.00View SEC Filing  
7/1/2016Eugene A BauerInsiderSell2,500$29.48$73,700.00View SEC Filing  
6/23/2016Luis C PenaInsiderSell10,000$30.01$300,100.00View SEC Filing  
6/15/2016Luis C PenaInsiderSell10,000$29.47$294,700.00View SEC Filing  
6/13/2016Christopher M GriffithVPSell4,405$30.16$132,854.80View SEC Filing  
6/1/2016Eugene A BauerInsiderSell2,500$31.65$79,125.00View SEC Filing  
6/1/2016Thomas G WiggansCEOSell11,000$31.57$347,270.00View SEC Filing  
5/2/2016Eugene A BauerInsiderSell2,500$25.09$62,725.00View SEC Filing  
5/2/2016Thomas G WiggansCEOSell9,000$25.11$225,990.00View SEC Filing  
4/1/2016Eugene A BauerInsiderSell2,500$20.84$52,100.00View SEC Filing  
4/1/2016Thomas G WiggansCEOSell7,000$20.69$144,830.00View SEC Filing  
3/1/2016Eugene A BauerInsiderSell2,500$22.55$56,375.00View SEC Filing  
3/1/2016Thomas G WiggansCEOSell7,000$22.57$157,990.00View SEC Filing  
2/1/2016Eugene A BauerInsiderSell2,500$27.26$68,150.00View SEC Filing  
2/1/2016Thomas G WiggansCEOSell9,000$27.25$245,250.00View SEC Filing  
1/4/2016Eugene A BauerInsiderSell2,500$33.17$82,925.00View SEC Filing  
1/4/2016Thomas G WiggansCEOSell11,000$33.17$364,870.00View SEC Filing  
12/1/2015Eugene A BauerInsiderSell2,500$29.65$74,125.00View SEC Filing  
11/2/2015Eugene A BauerInsiderSell2,500$27.82$69,550.00View SEC Filing  
10/1/2015Eugene A BauerInsiderSell2,500$22.87$57,175.00View SEC Filing  
9/14/2015Eugene A BauerInsiderSell22,500$28.05$631,125.00View SEC Filing  
11/25/2014Matthew K FustDirectorBuy6,000$16.77$100,620.00View SEC Filing  
10/8/2014Bay City Capital LlcDirectorBuy69,112$16.00$1,105,792.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Dermira (NASDAQ:DERM)
News IconStock Spotlight: Zooming in on Shares of Dermira, Inc. (NASDAQ:DERM) - The Standard (NASDAQ:DERM) - February 23 at 4:40 PM logoDermira to Report Fourth Quarter and Full Year 2016 Financial Results (NASDAQ:DERM) - February 22 at 4:56 PM
News IconChartists Perspective on Dermira, Inc. (NASDAQ:DERM) - Sherwood Daily (NASDAQ:DERM) - February 22 at 5:46 AM
News IconSmart Money Buying the Price Weakness of Dermira, Inc. (DERM) - Money Flow Index & Trends (NASDAQ:DERM) - February 22 at 5:46 AM
News IconDermira, Inc. (DERM): An Examination Of The Chart For Today's Session - NY Stock News (NASDAQ:DERM) - February 18 at 4:28 PM
News IconWall Street Ratings Review on Dermira, Inc. (NASDAQ:DERM) Green Bancorp, Inc. (NASDAQ:GNBC) - Rockville Register (NASDAQ:DERM) - February 18 at 4:28 PM logoDERM Crosses Above Key Moving Average Level (NASDAQ:DERM) - February 16 at 7:31 PM
News IconStock Chatter: Dermira, Inc. (NASDAQ:DERM) Price Target Update - Rockville Register (NASDAQ:DERM) - February 16 at 2:29 PM
News IconMarket Focus- Increased Volatility Recorded on Shares of Dermira, Inc. (NASDAQ:DERM) - Aiken Advocate (NASDAQ:DERM) - February 16 at 2:29 PM
News IconThe Role of Biologic Therapy for Psoriasis in Cardiovascular Risk Reduction (NASDAQ:DERM) - February 13 at 5:23 PM logoDermira to Present at Leerink Partners 6th Annual Global Healthcare Conference (NASDAQ:DERM) - February 8 at 5:08 PM logoCAM Group Holding A Buys Philip Morris International, Taiwan Semiconductor Manufacturing Co, ... (NASDAQ:DERM) - February 7 at 5:50 PM logoBRIEF-Jennison Associates reports 6.9 pct passive stake in Dermira (NASDAQ:DERM) - February 2 at 10:08 PM logoForm SC 13G Dermira, Inc. Filed by: PRUDENTIAL FINANCIAL INC (NASDAQ:DERM) - January 30 at 5:36 PM
News IconShares of Dermira, Inc. (DERM) Sees Large Outflow of Money - Highland Mirror (NASDAQ:DERM) - January 30 at 10:28 AM
News IconRSI Watch on Shares of Dermira Inc. (DERM) - Market Point (NASDAQ:DERM) - January 26 at 5:56 PM
News IconLarge Inflow of Money Witnessed in Dermira, Inc. - Highland Mirror (NASDAQ:DERM) - January 26 at 5:56 PM logoDermira: How Biosimilars Threaten Sales Of Cimzia (NASDAQ:DERM) - January 25 at 5:50 PM
News IconDermira Inc DERM Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:DERM) - January 23 at 7:37 AM
News IconCurrent Drive Leaders (NASDAQ:DERM) - January 22 at 9:39 PM
News IconTrading Corner: Eye on Technical Levels for Dermira Inc. (DERM) - Sherwood Daily (NASDAQ:DERM) - January 20 at 10:55 PM logoDERMIRA : Final CIMZIA (certolizumab pegol) Phase 3 Trial Meets Primary Efficacy Endpoint in Patients with Moderate-to-Severe Chronic Plaque Psoriasis (NASDAQ:DERM) - January 20 at 5:53 PM logoBRIEF-Final CIMZIA Phase 3 trial meets primary efficacy endpoint (NASDAQ:DERM) - January 19 at 6:00 PM logoUCB : Final CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Primary Efficacy … (NASDAQ:DERM) - January 19 at 6:00 PM logoDermira Up on Phase 3 Psoriasis Results (DERM) (NASDAQ:DERM) - January 19 at 6:00 PM logo3:35 am Dermira reports Phase 3 trial for CIMZIA meets primary endpoint (NASDAQ:DERM) - January 19 at 6:00 PM logoDermira Psoriasis Drug Cimzia Did Well In Study (NASDAQ:DERM) - January 19 at 6:00 PM
News IconStock Perspective: Dermira, Inc. (NASDAQ:DERM) Earnings in View - Aiken Advocate (NASDAQ:DERM) - January 19 at 3:09 AM logoFinal CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Primary Efficacy Endpoint in Patients with Moderate-to-Severe ... - GlobeNewswire (press release) (NASDAQ:DERM) - January 19 at 3:09 AM
News IconReg Filings: As Dermira INC (DERM) Market Valuation Rose, Dafna Capital Management LLC Lowered Position by ... - The Herald Beacon (NASDAQ:DERM) - January 19 at 3:09 AM logoFinal CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Primary Efficacy Endpoint in Patients with Moderate-to-Severe Chronic Plaque Psoriasis (NASDAQ:DERM) - January 19 at 3:09 AM
News IconStock Momentum Skidding to a Halt For Dermira, Inc. (NASDAQ:DERM) - Wall Street Beacon (NASDAQ:DERM) - January 17 at 5:32 PM
News IconTrading Scope: ADX and CCI Review for Dermira Inc. (DERM) - Springdale Times (NASDAQ:DERM) - January 17 at 8:20 AM logoDermira, Inc. (NASDAQ:DERM) Records An Impact Score Of 0 - Investor Newswire (NASDAQ:DERM) - January 15 at 4:32 PM logoBRIEF-Dermira provides corporate update (NASDAQ:DERM) - January 7 at 5:27 PM logoLori Lyons-Williams Joins Dermira as Chief Commercial Officer ... - GlobeNewswire (press release) (NASDAQ:DERM) - January 7 at 3:15 AM
News IconDermira Provides Corporate Update - EconoTimes (NASDAQ:DERM) - January 7 at 3:15 AM logoThe Heydar Aliyev airport served a record number of passengers in 2016 (NASDAQ:DERM) - January 6 at 5:10 PM
News IconDermira Elects To Board Of Directors (NASDAQ:DERM) - January 6 at 5:10 PM logoDermira Provides Corporate Update (NASDAQ:DERM) - January 6 at 5:10 PM logoZuma ensures a place for SA on the ‘top 10 risks to the world list’ (NASDAQ:DERM) - January 5 at 5:26 PM logoDermira (DERM) Appoints Lori Lyons-Williams to CCO (NASDAQ:DERM) - January 5 at 5:26 PM logoLori Lyons-Williams Joins Dermira as Chief Commercial Officer (NASDAQ:DERM) - January 5 at 5:26 PM logoDermira, Inc. breached its 50 day moving average in a Bullish Manner : DERM-US : January 5, 2017 (NASDAQ:DERM) - January 5 at 5:26 PM
News IconNasdaq Holds Fourth Quarter 2016 Investor Conference Call (NASDAQ:DERM) - January 4 at 5:46 PM logoDERMIRA, INC. Files SEC form 8-K/A, Change in Directors or Principal Officers (NASDAQ:DERM) - January 4 at 5:46 PM logoDermira Elects Emmanuel Caeymaex to Board of Directors (NASDAQ:DERM) - January 4 at 5:46 PM logoAnalyst Activity – SEB Equity Research Reiterates Reduce on Dermira (NASDAQ:DERM) - Market Exclusive (NASDAQ:DERM) - January 4 at 6:43 AM logoAnalyst Activity – SEB Equity Research Reiterates Reduce on Dermira (NASDAQ:DERM) (NASDAQ:DERM) - January 3 at 11:28 PM
News IconDermira Initiates Phase 3 Clinical Program in Acne - EconoTimes - EconoTimes (NASDAQ:DERM) - January 3 at 12:34 PM


What is Dermira's stock symbol?

Dermira trades on the NASDAQ under the ticker symbol "DERM."

Where is Dermira's stock going? Where will Dermira's stock price be in 2017?

5 equities research analysts have issued 12 month price objectives for Dermira's shares. Their predictions range from $40.00 to $47.00. On average, they anticipate Dermira's share price to reach $44.75 in the next twelve months.

When will Dermira announce their earnings?

Dermira is scheduled to release their next quarterly earnings announcement on Wednesday, March, 1st 2017.

Who owns Dermira stock?

Dermira's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (13.23%), UCB SA (7.50%), State Street Corp (1.44%), Loomis Sayles & Co. L P (1.21%), Orbimed Advisors LLC (1.20%) and Perceptive Advisors LLC (0.91%). Company insiders that own Dermira stock include Andrew Guggenhime, Christopher M Griffith, Eugene A Bauer, Luis C Pena, Thomas G Wiggans and William R Ringo.

Who sold Dermira stock? Who is selling Dermira stock?

Dermira's stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, State Street Corp, Century Capital Management LLC, Fred Alger Management Inc., Nicholas Investment Partners LP, Acuta Capital Partners LLC, Allianz Asset Management AG and Boothbay Fund Management LLC. Company insiders that have sold Dermira stock in the last year include Andrew Guggenhime, Christopher M Griffith, Eugene A Bauer, Luis C Pena, Thomas G Wiggans and William R Ringo.

Who bought Dermira stock? Who is buying Dermira stock?

Dermira's stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Perceptive Advisors LLC, Novo A S, New Leaf Venture Partners L.L.C., Clough Capital Partners L P, Loomis Sayles & Co. L P, Marshall Wace LLP and Advisory Research Inc..

How do I buy Dermira stock?

Shares of Dermira can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Dermira stock cost?

One share of Dermira stock can currently be purchased for approximately $33.20.

Dermira (NASDAQ:DERM) Chart for Saturday, February, 25, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Dermira (NASDAQ:DERM)

Earnings History Chart

Earnings by Quarter for Dermira (NASDAQ:DERM)

Dividend History Chart

Dividend Payments by Quarter for Dermira (NASDAQ:DERM)

Last Updated on 2/25/2017 by Staff